These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20187101)

  • 1. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.
    Kay NE; Wu W; Kabat B; LaPlant B; Lin TS; Byrd JC; Jelinek DF; Grever MR; Zent CS; Call TG; Shanafelt TD
    Cancer; 2010 May; 116(9):2180-7. PubMed ID: 20187101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
    Kay NE; Geyer SM; Call TG; Shanafelt TD; Zent CS; Jelinek DF; Tschumper R; Bone ND; Dewald GW; Lin TS; Heerema NA; Smith L; Grever MR; Byrd JC
    Blood; 2007 Jan; 109(2):405-11. PubMed ID: 17008537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
    Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
    Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.
    Lamanna N; Kalaycio M; Maslak P; Jurcic JG; Heaney M; Brentjens R; Zelenetz AD; Horgan D; Gencarelli A; Panageas KS; Scheinberg DA; Weiss MA
    J Clin Oncol; 2006 Apr; 24(10):1575-81. PubMed ID: 16520464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
    Reynolds C; Di Bella N; Lyons RM; Hyman W; Richards DA; Robbins GJ; Vellek M; Boehm KA; Zhan F; Asmar L
    Invest New Drugs; 2012 Jun; 30(3):1232-40. PubMed ID: 21922186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).
    Kempin S; Sun Z; Kay NE; Paietta EM; Mazza JJ; Ketterling RP; Frankfurt O; Claxton DF; Saltzman JN; Srkalovic G; Callander NS; Gross G; Tallman MS
    Acta Haematol; 2019; 142(4):224-232. PubMed ID: 31336367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
    Zent CS; Taylor RP; Lindorfer MA; Beum PV; LaPlant B; Wu W; Call TG; Bowen DA; Conte MJ; Frederick LA; Link BK; Blackwell SE; Veeramani S; Baig NA; Viswanatha DS; Weiner GJ; Witzig TE
    Am J Hematol; 2014 Jul; 89(7):757-65. PubMed ID: 24723493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
    Shanafelt TD; Lin T; Geyer SM; Zent CS; Leung N; Kabat B; Bowen D; Grever MR; Byrd JC; Kay NE
    Cancer; 2007 Jun; 109(11):2291-8. PubMed ID: 17514743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
    Weiss MA; Maslak PG; Jurcic JG; Scheinberg DA; Aliff TB; Lamanna N; Frankel SR; Kossman SE; Horgan D
    J Clin Oncol; 2003 Apr; 21(7):1278-84. PubMed ID: 12663715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.
    Kay NE; Strati P; LaPlant BR; Leis JF; Nikcevich D; Call TG; Pettinger AM; Lesnick CE; Hanson CA; Shanafelt TD
    Oncotarget; 2016 Nov; 7(48):78269-78280. PubMed ID: 27861157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
    Awan FT; Kay NE; Davis ME; Wu W; Geyer SM; Leung N; Jelinek DF; Tschumper RC; Secreto CR; Lin TS; Grever MR; Shanafelt TD; Zent CS; Call TG; Heerema NA; Lozanski G; Byrd JC; Lucas DM
    Blood; 2009 Jan; 113(3):535-7. PubMed ID: 19008456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia.
    Kay NE; LaPlant BR; Pettinger AM; Call TG; Leis JF; Ding W; Parikh SA; Conte MJ; Bowen DA; Shanafelt TD
    Expert Rev Hematol; 2018 Apr; 11(4):337-349. PubMed ID: 29460654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
    J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of resistant/relapsing chronic lymphocytic leukemia with a combination regimen containing deoxycoformycin and rituximab.
    Tsiara SN; Kapsali HD; Chaidos A; Christou L; Bourantas KL
    Acta Haematol; 2004; 111(4):185-8. PubMed ID: 15153709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Byrd JC; Kipps TJ; Flinn IW; Castro J; Lin TS; Wierda W; Heerema N; Woodworth J; Hughes S; Tangri S; Harris S; Wynne D; Molina A; Leigh B; O'Brien S
    Blood; 2010 Jan; 115(3):489-95. PubMed ID: 19843887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I and II study of pentostatin (Nipent) with cyclophosphamide for previously treated patients with chronic lymphocytic leukemia.
    Weiss MA
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):41-3. PubMed ID: 10877051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.
    Stephens DM; Ruppert AS; Maddocks K; Andritsos L; Baiocchi R; Jones J; Johnson AJ; Smith LL; Zhao Y; Ling Y; Li J; Phelps MA; Grever MR; Byrd JC; Flynn JM
    Leuk Res; 2013 Oct; 37(10):1195-9. PubMed ID: 23867058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.